Venus Remedies Secures Ukrainian GMP Renewal, Boosting Global Pharmaceutical Presence
Venus Remedies Limited, a leading global pharmaceutical company, has successfully renewed its Good Manufacturing Practices (GMP) certification from Ukraine's State Service on Medicines and Drugs Control (SMDC) for its Unit-l1 manufacturing facility in Baddi, Himachal Pradesh. The certification, covering cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral production lines, strengthens Venus Remedies' position in PIC/S markets and reinforces its commitment to global quality standards. The Ukrainian pharmaceutical market, projected to grow at a CAGR of 3.9% and reach US$822.26 million by 2029, is a key strategic market for the company, with over two decades of experience and 44 product registrations in Ukraine.
Key Highlights
- Venus Remedies secures Ukrainian GMP renewal for its Unit-l1 manufacturing facility in Baddi, Himachal Pradesh.
- The certification covers cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral production lines, including liquid and lyophilized injections.
- Renewal reinforces Venus Remedies' commitment to maintaining world-class manufacturing standards and enhances its foothold in the Ukrainian market.
- The certification facilitates deeper penetration into PIC/S markets, significantly enhancing international growth prospects.
- Ukraine is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Venus Remedies has a robust presence in 32 PIC/S countries.